Shareholders' Equity

9 Months Ended

Mar. 31, 2025

Equity [Abstract]

Shareholders' Equity

11. Shareholders' Deficit

We repurchased $750 million of our common shares, in the aggregate, through share repurchase programs during both the nine months ended March 31, 2025 and 2024. We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes.

During the three months ended March 31, 2025, we entered into an accelerated share repurchase ("ASR") program to repurchase common shares for an aggregate purchase price of $375 million. We received an initial delivery of 2.4 million common shares using a reference price of $125.33. The program concluded on March 11, 2025 at a volume weighted average price per common share of $125.87 resulting in a final delivery of 0.6 million common shares.

During the nine months ended March 31, 2025, we paid $15 million for excise taxes related to the completion of prior ASR programs.

During the three months ended December 31, 2024, we retired 56 million of common stock shares without par value.

During the three months ended September 30, 2024, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $375 million. We received an initial

delivery of 2.7 million common shares using a reference price of $109.65. The program concluded on October 30, 2024 at a volume weighted average price per common share of $110.10 resulting in a final delivery of 0.7 million common shares.

During the three months ended December 31, 2023, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $250 million. We received an initial delivery of 2.0 million common shares using a reference price of $101.66. The program concluded on December 13, 2023 at a volume weighted average price per common share of $103.67 resulting in a final delivery of 0.4 million common shares.

During the three months ended September 30, 2023, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $500 million. We received an initial delivery of 4.4 million common shares using a reference price of $90.57. The program concluded on October 31, 2023 at a volume weighted average price per common share of $88.22 resulting in a final delivery of 1.3 million common shares.

Accumulated Other Comprehensive Loss

The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:

(in millions)	Foreign Currency Translation Adjustments		Unrealized Gain/(Loss) on Derivatives, net of tax		Accumulated Other Comprehensive Loss
Balance at June 30, 2024	$	(138)	$	(29)	$	(167)
Other comprehensive income/(loss), before reclassifications	(13)		3		(10)
Amounts reclassified to earnings	—		1		1
Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax benefit of $2 million	(13)		4		(9)
Balance at March 31, 2025	$	(151)	$	(25)	$	(176)

(in millions)	Foreign Currency Translation Adjustments		Unrealized Gain/(Loss) on Derivatives, net of tax		Accumulated Other Comprehensive Loss
Balance at June 30, 2023	$	(137)	$	(14)	$	(151)
Other comprehensive income/(loss), before reclassifications	(4)		1		(3)
Amounts reclassified to earnings	—		(6)		(6)
Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax expense of $4 million	(4)		(5)		(9)
Balance at March 31, 2024	$	(141)	$	(19)	$	(160)